Background rates of 41 adverse events of special interest for COVID-19 vaccines in 10 European healthcare databases - an ACCESS cohort study.

BACKGROUND: In May 2020, the ACCESS (The vACCine covid-19 monitoring readinESS) project was launched to prepare real-world monitoring of COVID-19 vaccines. Within this project, this study aimed to generate background incidence rates of 41 adverse events of special interest (AESI) to contextualize potential safety signals detected following administration of COVID-19 vaccines. METHODS: A dynamic cohort study was conducted using a distributed data network of 10 healthcare databases from 7 European countries (Italy, Spain, Denmark, The Netherlands, Germany, France and United Kingdom) over the period 2017 to 2020. A common protocol (EUPAS37273), common data model, and common analytics programs were applied for syntactic, semantic and analytical harmonization. Incidence rates (IR) for each AESI and each database were calculated by age and sex by dividing the number of incident cases by the total person-time at risk. Age-standardized rates were pooled using random effect models according to the provenance of the events. FINDINGS: A total number of 63,456,074 individuals were included in the study, contributing to 211.7 million person-years. A clear age pattern was observed for most AESIs, rates also varied by provenance of disease diagnosis (primary care, specialist care). Thrombosis with thrombocytopenia rates were extremely low ranging from 0.06 to 4.53/100,000 person-years for cerebral venous sinus thrombosis (CVST) with thrombocytopenia (TP) and mixed venous and arterial thrombosis with TP, respectively. INTERPRETATION: Given the nature of the AESIs and the setting (general practitioners or hospital-based databases or both), background rates from databases that show the highest level of completeness (primary care and specialist care) should be preferred, others can be used for sensitivity. The study was designed to ensure representativeness to the European population and generalizability of the background incidence rates. FUNDING: The project has received support from the European Medicines Agency under the Framework service contract nr EMA/2018/28/PE.

Influencia del suero fetal bovino en el cultivo de fibroblastos gingivales / Influence of bovine fetal serum in the culture of gingival fibroblasts

Introducción: Los fibroblastos gingivales (FGs) son células responsables del mantenimiento de la homeostasis, cicatrización y tolerancia inmunitaria del tejido conjuntivo gingival. Por sus características fisiológicas, los FGs pueden ser un candidato en la terapia celular. Sin embargo, la conservación de su fenotipo en cultivo celulares requiere de condiciones estrictamente definidas. Una de ellas es la concentración de Suero Fetal Bovino (SFB). Nuestro objetivo es evaluar el efecto concentración-dependiente de la suplementación de SFB en el medio de cultivo sobre el comportamiento, crecimiento, proliferación y supervivencia de los fibroblastos gingivales humanos. Materiales y métodos: FGs fueron cultivados con DMEM (Dulbecco's modification of Eagle médium) y concentraciones de 0%, 0.5% y 10% de SFB durante tres semanas. Análisis morfológico, de proliferación e inmunohistoquímicos fueron llevados a cabo en el presente trabajo. Se llevó a cabo un análisis factorial de varianza (ANOVA) por medio el software R Project. Los resultados fueron considerados significativos con un valor de p<0,05. Resultados y Discusión: Los FGs cultivados con 10% de SFB alcanzaron un desarrollo morfológico más notorio y en menor tiempo comparados con los FGs cultivados a 0.5% y 0% de SFB. La efectividad de la concentración del SFB 0,5% fue mucho más alta en relación a la concentración del SFB 10%. La inmunodetención de la actina, vimentina y fibronectina fueron más notorias en los FGs tratados con 10% y 0.5% de SFB. Este estudio concluye que los FGs humanos presentan una mejor capacidad de supervivencia, desarrollo y proliferación cuando son cultivados en presencia de SFB

Introduction: Gingival fibroblasts (FGs) are cells responsible for the maintenance of homeostasis, healing and immune tolerance of the gingival connective tissue. Due to their physiological characteristics, FGs can be a candidate in cell therapy. However, the conservation of their phenotype in cell culture requires strictly defined conditions. One of them is the concentration of Bovine Fetal Serum (FBS). Our aim is to evaluate the concentration-dependent effect of SFB supplementation in the culture medium on the behavior, growth, proliferation and survival of human gingival fibroblasts. Materials and methods: FGs were cultured with DMEM (Dulbecco's modification of Eagle medium) and concentrations of 0%, 0.5% and 10% of SFB for three weeks. Morphological, proliferation and immunohistochemical analyzes were carried out in the present work. A factorial analysis of variance (ANOVA) was carried out using the R Project software. The results were considered significant with a value of p <0.05. Results and discussion: The FGs grown with 10% FBS reached a more noticeable morphological development and in a shorter time compared to the FGs grown at 0.5% and 0% FBS. The effectiveness of the concentration of the SFB 0.5% was much higher in relation to the concentration of the SFB 10%. The immunodetention of actin, vimentin and fibronectin were more evident in the FGs treated with 10% and 0.5% FBS. This study concludes that human FGs have a better capacity for survival, development and proliferation when they are grown in the presence of FBS